NLTX News and Press, Neoleukin Therapeutics Inc. From 09/09/21

SEATTLE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Bill Arthur, Ph.D., as ...

SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Execut...

Gainers: Support.com SPRT +173%. NeuroMetrix (NASDAQ:NURO) +90%. Navios Maritime Acquisition NNA +56%. Vinco Ventures (NASDAQ:BBIG) +49%. Aterian (NASDAQ:ATER) +31%. Marin Software Incorporated (NASDAQ:MRIN) +29%. Gambling.com Group GAMB +29%. Bill.com BILL +28%. Meta Mate...

Gainers: NeuroMetrix (NASDAQ:NURO) +54%, Reneo Pharmaceuticals (NASDAQ:RPHM) +24%, Neoleukin Therapeutics (NASDAQ:NLTX) +21%, Chembio Diagnostics (NASDAQ:CEMI) +17%, InspireMD (NASDAQ:NSPR) +14%. Losers: Cassava Sciences (NASDAQ:SAVA) -28%, Applied Ther...

Today, we look back in on Neoleukin Therapeutics for the first time since the first quarter of 2020. The company's developmental platform remains intriguing and Neoleukin is well funded to continue to push its pipeline forward. A full investment analysis follows in the paragraphs ...

Neoleukin Therapeutics (NASDAQ:NLTX): Q2 GAAP EPS of -$0.27 in-line. Cash and cash equivalents of $164.2M Press Release For further details see: Neoleukin Therapeutics EPS in-line

SEATTLE, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the second quarter en...

SEATTLE, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executi...

Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...

SEATTLE, May 26, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executiv...